IP Library Granted Patent US 9,504,771
Granted Patent B2
US 9,504,771 · App. 13/103,885 · Granted Nov 29, 2016

Drug eluting composite

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,504,771
App. No.
13/103,885
Granted
Nov 29, 2016
Kind
B2
Abstract

The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Claims (36)

1. A method for designing a therapeutic-releasing construction comprising:

providing a polymeric material that comprises a therapeutic composition, wherein the polymeric material is surrounded by an impermeable capping layer;

determining a desired elution rate;

designing said therapeutic-releasing construction comprising said polymeric material and a plurality of biocompatible polymeric barriers that define an elution pathway within said polymeric material, wherein the designing comprises configuring said elution pathway within the polymeric material to deliver the therapeutic composition from a starting position within the polymeric material to a release point in the polymeric material, the plurality of biocompatible polymeric barriers having a height such that each of said plurality of biocompatible polymeric barriers extends a full vertical distance between an inner surface and the outer surface of the polymeric material, and the elution pathway being configured structurally using said plurality of biocompatible polymeric barriers within the polymeric material to alter one or more of geometry, tortuosity, diffusion length, diffusion coefficient, and void volume of the elution pathway;

predicting an elution rate of the therapeutic-releasing construction based on the geometry, the tortuosity, the diffusion length, the diffusion coefficient, and the void volume of the elution pathway; and

verifying that said therapeutic-releasing construction will deliver said therapeutic composition according to said desired elution rate based on the designing of said therapeutic-releasing construction and said predicting of said elution rate.

2. The method of claim 1 , wherein said step of predicting further comprises using computational fluid dynamics.

3. The method of claim 1 further comprising a step of re-designing the therapeutic-releasing construction if it cannot be verified that said therapeutic-releasing construction will deliver said therapeutic composition according to said desired elution rate.

4. A therapeutic-releasing construction comprising:

a biocompatible construction substantially impermeable to a therapeutic agent and containing said therapeutic agent;

a plurality of biocompatible polymeric barriers substantially impermeable to said therapeutic agent disposed within said biocompatible construction and having a height such that each of said plurality of biocompatible polymeric barriers extends a full vertical distance between an inner surface and the outer surface of the biocompatible construction; and

an elution pathway within said biocompatible construction defined by said plurality of biocompatible polymeric barriers;

wherein said elution pathway has a lower tortuosity section and a higher tortuosity section, and

wherein a formed opening is in communication with said elution pathway.

5. The therapeutic-releasing construction of claim 4 wherein said lower tortuosity section and said higher tortuosity section are separated by a temporary gate.

6. The therapeutic-releasing construction of claim 4 wherein said lower tortuosity section is configured for short term delivery and said higher tortuosity section is configured for long term delivery.

7. The therapeutic-releasing construction of claim 4 wherein said therapeutic agent is dexamethasone sodium phosphate.

8. A therapeutic-releasing construction comprising:

a biocompatible construction substantially impermeable to a therapeutic agent and containing said therapeutic agent;

a plurality of biocompatible polymeric barriers substantially impermeable to said therapeutic agent disposed within said biocompatible construction; and

a slower elution pathway and a faster elution pathway defined by said plurality of biocompatible polymeric barriers;

wherein an opening through said biocompatible construction is in communication with at least one of said slower elution pathway and said faster elution pathway and

each of said plurality of biocompatible polymeric barriers is positioned perpendicular to a longitudinal center line of the therapeutic-releasing construction, and each of said plurality of biocompatible polymeric barriers has a length such that each of said plurality of biocompatible polymeric barriers extends from a first edge of therapeutic-releasing construction towards a second edge of the therapeutic-releasing construction, and ends a predetermined distance away from the second edge.

9. The therapeutic-releasing construction of claim 8 wherein said slower elution pathway is characterized by a first tortuosity and said faster elution pathway is characterized by a second tortuosity less than said first tortuosity.

10. The therapeutic-releasing construction of claim 8 wherein said slower elution pathway is characterized by a first diffusion length and said faster elution pathway is characterized by a second diffusion length less than said first diffusion length.

11. A therapeutic agent-releasing construction comprising:

a first biocompatible polymeric material having a surface and having a therapeutic agent loaded strip disposed on the surface;

a capping layer substantially impermeable to said therapeutic agent and covering substantially all of said therapeutic agent loaded strip;

a biocompatible polymeric barrier disposed within the first biocompatible polymeric material and having a height such that said biocompatible polymeric barrier extends a full vertical distance between the capping layer covering an inner surface of the first biocompatible material and the capping layer covering an outer surface of the first biocompatible material, wherein the biocompatible polymeric barrier separates the first biocompatible polymeric material into a first side and second side, said biocompatible polymeric barrier and the capping layer structurally define an elution pathway;

at least one temporary gate extending across said elution pathway at a point along said elution pathway at said biocompatible polymeric barrier, wherein said at least one temporary gate is configured to open and release said therapeutic agent from said first side to said second side; and

at least one formed opening in said capping layer in communication with said elution pathway.

12. The therapeutic-releasing construction of claim 11 wherein said therapeutic agent is disposed on said first side of said at least one gate and a second therapeutic agent is disposed on said second side of said at least one gate.

13. The therapeutic-releasing construction of claim 11 wherein a first potency of said therapeutic agent is disposed on said first side of said at least one gate and a second potency of said therapeutic agent is disposed on said second side of said at least one gate.

14. The therapeutic-releasing construction of claim 11 wherein said first biocompatible polymeric material comprises a fluoropolymer composition.

15. The therapeutic-releasing construction of claim 14 wherein said fluoropolymer is porous polytetrafluoroethylene.

16. The therapeutic-releasing construction of claim 11 wherein said capping layer and biocompatible polymeric barrier are a silicone composition.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2012
From: GORE ENTERPRISE HOLDINGS, INC.
To: W. L. GORE & ASSOCIATES, INC.
Reel/Frame 027906/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2011
From: CLEEK, ROBERT L.; CULLY, EDWARD H.; DUNCAN, JEFFREY B.; HOLLAND, THERESA A.; MCDANIEL, THOMAS R.; SCOTTI, CHRISTINE M.
To: GORE ENTERPRISE HOLDINGS, INC.
Reel/Frame 026617/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2011
From: CLEEK, ROBERT L.; CULLY, EDWARD H.; DUNCAN, JEFFREY B.; HOLLAND, THERESA A.; MCDANIEL, THOMAS R.; SCOTTI, CHRISTINE M.
To: GORE ENTERPRISE HOLDINGS, INC.
Reel/Frame 026617/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2011
From: CLEEK, ROBERT L.; CULLY, EDWARD H.; DUNCAN, JEFFREY B.; HOLLAND, THERESA A.; MCDANIEL, THOMAS R.; SCOTTI, CHRISTINE M.
To: GORE ENTERPRISE HOLDINGS, INC.
Reel/Frame 026617/0525 →